1 Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.
2 Department of Transplantation - Liver Unit, Cardarelli Hospital, Naples, Italy.
Cancer Biother Radiopharm. 2019 May;34(4):231-237. doi: 10.1089/cbr.2018.2718. Epub 2019 Feb 13.
The aim of this study was to evaluate the safety and efficacy of repeated administration of Y-microspheres in intrahepatic cholangiocarcinoma (ICC) relapsed after the first radioembolization (RE). Nine patients with ICC relapsed after the first Y-RE were enrolled. Six patients presented recurrence in the right hepatic lobe, 3 in the left lobe. All subjects underwent a second administration of Y-resin microspheres. Toxicity was assessed according to Common Terminology Criteria for Adverse Events (CTCAE, version 4.02). After the repeated treatment, all patients were submitted to follow-up with laboratory, imaging, and clinical examinations. The mean cumulative activity administered considering both treatments was 2.7 ± 0.5 GBq. After the second treatment, 3 patients presented complete metabolic response (33.3%) and 6 had partial response (66.6%). The following adverse events were registered: transient increased levels of liver enzymes (grade 1 = 4; grade 2 = 2), hyperbilirubinemia (grade 1 = 2), ascites (grade 2 = 1), and duodenal ulcer (grade 2 = 1). Two patients developed a significant shrinking of the targeted hepatic lobe, as for radiation lobectomy. No case of RE-induced liver disease was registered. Median overall survival was 16.5 ± 1.4 months after the first RE. The authors' results suggest that repeated administration of Y-microspheres may be considered in patients affected by ICC relapsed after the first Y-RE.
本研究旨在评估 Y 微球在首次放射性栓塞(RE)后复发的肝内胆管癌(ICC)患者中重复给药的安全性和疗效。
本研究纳入了 9 例首次 Y-RE 后复发的 ICC 患者。6 例患者右肝复发,3 例患者左肝复发。所有患者均行第二次 Y 树脂微球治疗。毒性评估采用不良事件通用术语标准(CTCAE,版本 4.02)。重复治疗后,所有患者均接受实验室、影像学和临床检查随访。
两次治疗累积给予的平均活度为 2.7±0.5GBq。第二次治疗后,3 例患者完全代谢缓解(33.3%),6 例患者部分缓解(66.6%)。登记的不良反应如下:一过性肝酶水平升高(1 级=4;2 级=2)、高胆红素血症(1 级=2)、腹水(2 级=1)和十二指肠溃疡(2 级=1)。2 例患者发生靶向肝叶显著缩小,类似肝叶切除术的效果。未发生 RE 相关性肝病。首次 RE 后中位总生存期为 16.5±1.4 个月。
作者的结果表明,对于首次 Y-RE 后复发的 ICC 患者,可考虑重复给予 Y 微球。